HealthDay News — For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual ...

US-based patients with idiopathic pulmonary fibrosis (IPF) had a slower decline in forced vital capacity (FVC) when they received nerandomilast (Jascayd; Boehringer Ingelheim) compared with placebo, a ...

Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL ...

Dupilumab reduces mucus plug scores and improves lung function in patients with moderate-to-severe asthma and high baseline mucus plug scores, according to a study published online Oct. 2 in ...

Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...

FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or ...

Fibrotic interstitial lung disease (fibrotic ILD) entails a spectrum of different clinical entities characterised by an ...

On Oct. 20, Chicago Fire Department firefighters had the opportunity to get screened for COPD at Station 18, thanks to a ...

Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational benefits to patients with life-threatening diseases, ...

Good afternoon, and welcome to Sarepta's Third Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, ...

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...